Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca and Forest Laboratories ‘to collaborate on ceftaroline’

AstraZeneca and Forest Laboratories ‘to collaborate on ceftaroline’

12th August 2009

AstraZeneca and Forest Laboratories have agreed to collaborate on the development and commercialisation of ceftaroline, it has emerged.

Providing the product to all markets outside of Canada, Japan and the US, the companies will work together to develop and manufacture ceftaroline – Forest’s late-stage next generation cephalosporin for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).

As part of the agreement, AstraZeneca will pay Forest a fee while assuming responsibility for the regulatory approval, commercialisation and development of ceftaroline.

AstraZeneca’s chief executive David Brennan said that the two firms aim to collaborate to tackle the growing issue of antibiotic resistance.

“This collaboration complements our existing antibiotic MerremTM and our significant investment in antibiotic research, as well as agents in development such as CytoFabTM,” he added.

Forest Laboratories, which has its headquarters in New York, has a long history of development and marketing-based collaborations.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.